PTPN6 and pulmonary fibrosis: Decreased circulating monocytes as a result of SC-43 treatment against bleomycin-induced pulmonary fibrosis corroborates the efficacy of the SHP-1 agonist, as increased monocyte counts have been linked disease progression in IPF patients [41, 42].